Antihypertensives — Onset & Duration

Diagnostic Distinction

In the acute care setting, elevated BP falls into two categories with fundamentally different management 2024 AHA Acute-Care BP Statement:

Hypertensive emergency: elevated BP with signs of new or worsening target-organ damage (AKI, encephalopathy, pulmonary edema, type 2 MI, papilledema). Treat swiftly with IV agents in a closely monitored setting 2024 AHA Acute-Care BP Statement.
Asymptomatic elevated BP: elevated BP without acute target-organ damage. The risk-benefit ratio of initiating or intensifying antihypertensives is unclear, and observational studies have suggested potential harms from acute treatment 2024 AHA Acute-Care BP Statement. The term “hypertensive urgency” is not used in the current AHA acute-care statement.

IV Antihypertensives — Reference Table

Drug	Class	Onset	Duration	Dose	Key Cautions
Clevidipine	DHP CCB	2–4 min	5–15 min	1–16 mg/hr drip	Soy/egg allergy; avoid in ACS Peixoto 2019
Nitroglycerin	Nitrate vasodilator	1–5 min	5–10 min	10–400 µg/min drip	Tachyphylaxis; avoid in RV infarct Peixoto 2019
Nitroprusside	Direct vasodilator	1–2 min	1–2 min	0.25–10 µg/kg/min drip	Cyanide/thiocyanate toxicity; avoid in pregnancy Peixoto 2019
Phentolamine	α-blocker	1–2 min	10–30 min	5 mg IV bolus q10min	Catecholamine excess states only 2025 ACC/AHA BP
Nicardipine	DHP CCB	2–5 min	1–4 hr	5–15 mg/hr drip	Reflex tachycardia; avoid in ACS Peixoto 2019
Esmolol	β1-blocker	2–10 min	10–30 min	500–1000 µg/kg bolus → 100–300 µg/kg/min drip	Avoid in HF, bradycardia, asthma Peixoto 2019
Labetalol IV	α/β-blocker	5 min	3–6 hr	10–80 mg bolus or 0.5–10 mg/min drip (max 300 mg)	Avoid in HF, bradycardia, asthma Peixoto 2019
Fenoldopam	DA1 agonist	5–15 min	30–60 min	0.1–1.6 µg/kg/min drip	Avoid in glaucoma, ↑ ICP 2025 ACC/AHA BP
Metoprolol IV	β1-blocker	15 min	4–6 hr	2.5–5 mg q5min (max 15 mg)	Not very potent antihypertensive Peixoto 2019
Hydralazine IV	Direct vasodilator	10–30 min	3–6 hr	5–20 mg q15–20 min	Unpredictable response; not first-line per 2025 guideline 2025 ACC/AHA BP Bakkila 2026

Key points: Clevidipine and esmolol have the shortest durations, making them ideal when tight, rapidly titratable BP control is needed (e.g., aortic dissection) Peixoto 2019. Hydralazine IV is considered an undesirable first-line agent per the 2025 ACC/AHA guideline due to unpredictable responses and prolonged duration 2025 ACC/AHA BP Bakkila 2026.

Oral Antihypertensives — Outpatient Reference

These are outpatient chronic-therapy references. For acute care, see the sections below on asymptomatic elevated BP and hypertensive emergency.

Drug	Class	Onset (PO)	Half-life	Usual Dose	Key Notes
Captopril	ACE inhibitor	15–30 min	1.9 hr	25–50 mg BID-TID	Fastest-onset oral ACE inhibitor Peixoto 2019 Wang 2018
Clonidine PO	Central α2-agonist	30–60 min	12–16 hr	0.1–0.3 mg	Rebound HTN on withdrawal 2025 ACC/AHA BP Carey 2022
Hydralazine PO	Direct vasodilator	20–40 min	2–4 hr	25–100 mg BID-TID	Reflex tachycardia; use with β-blocker 2025 ACC/AHA BP
Labetalol PO	α/β-blocker	30–120 min	6–8 hr	200–400 mg	— Carey 2022
Enalapril	ACE inhibitor	1 hr	11 hr	5–40 mg daily/BID	Cough, angioedema Peixoto 2019 Taler 2018
Lisinopril	ACE inhibitor	1–2 hr	12 hr	10–40 mg daily	Cough, angioedema; avoid in pregnancy Peixoto 2019 Taler 2018
Losartan	ARB	1–2 hr	2 hr	25–100 mg daily/BID	Shortest-acting ARB Peixoto 2019 Taler 2018
Telmisartan	ARB	1–2 hr	24 hr	20–80 mg daily	Longest half-life ARB Peixoto 2019
Nifedipine ER	DHP CCB	1–2 hr	~2 hr (parent)	30–120 mg daily	Avoid immediate-release sublingual Wang 2018 Carey 2022
Verapamil ER	Non-DHP CCB	1–2 hr	12–17 hr (ER)	100–480 mg daily	Constipation; avoid in HFrEF Wang 2018 Taler 2018
Metoprolol succinate	β-blocker	1–2 hr	3–7 hr	50–200 mg daily	First-line only in IHD/HF 2025 ACC/AHA BP Taler 2018
Carvedilol	α/β-blocker	1–2 hr	7–10 hr	3.125–25 mg BID	— Taler 2018
HCTZ	Thiazide	2 hr	6–15 hr	12.5–50 mg daily	— Peixoto 2019 Taler 2018
Valsartan	ARB	2–4 hr	6 hr	80–320 mg daily	— Peixoto 2019 Taler 2018
Diltiazem ER	Non-DHP CCB	2–3 hr	3–9.5 hr (ER)	120–360 mg daily	Avoid with β-blockers; avoid in HFrEF Wang 2018 Taler 2018
Chlorthalidone	Thiazide-like	2–6 hr	~40 hr	12.5–25 mg daily	Preferred thiazide; hyponatremia risk in elderly Peixoto 2019 2025 ACC/AHA BP
Amlodipine	DHP CCB	6–12 hr (peak)	30–55 hr	2.5–10 mg daily	Preferred DHP CCB; peripheral edema Peixoto 2019 2025 ACC/AHA BP

Key points: Amlodipine has the slowest onset (peak 6–12 hr) and is not useful for acute BP lowering 2025 ACC/AHA BP. Immediate-release nifedipine should be avoided for acute BP lowering Peixoto 2019.

Hypertensive Emergency

Hypertensive emergency is defined by elevated BP with acute target-organ damage. It requires IV therapy in a closely monitored setting 2024 AHA Acute-Care BP Statement Peixoto 2019.

Evaluation

CBC, CMP, PT/INR, PTT
Troponin + EKG
Urinalysis
Urine toxicology screen Peixoto 2019
b-hCG

Treatment Goals

Cause-Specific Agent Selection

The choice of IV agent depends on the specific target-organ damage. The table below maps each hypertensive emergency cause to the preferred agent and rationale.

Cause	Preferred Agent(s)	Rationale
Aortic dissection	Esmolol + nicardipine or clevidipine	Reduce heart rate and shear force first; esmolol has shortest duration for tight titration 2025 ACC/AHA BP Peixoto 2019
SCAPE / flash pulmonary edema	Nitroglycerin (low-dose venodilation) ± nitroprusside	Venodilation reduces preload; avoid β-blockers in acute pulmonary edema Peixoto 2019
Acute ischemic stroke	Nicardipine or clevidipine	Titratable, predictable; permissive hypertension (≤220/120) unless thrombolysis candidate 2025 ACC/AHA BP
Acute hemorrhagic stroke	Nicardipine or clevidipine	Tight SBP control (target <140–160 depending on hematoma); avoid nitroprusside (↑ ICP) Peixoto 2019
Hypertensive encephalopathy / PRES	Nicardipine, labetalol, or clevidipine	Rapid, controlled reduction; avoid nitroprusside (↑ ICP, cyanide risk) Peixoto 2019
Acute coronary syndrome	Nitroglycerin ± β-blocker (esmolol or metoprolol)	Nitrates relieve ischemia; β-blockers reduce myocardial O2 demand Peixoto 2019
Pre-eclampsia / eclampsia	Labetalol IV or hydralazine IV	Preferred agents in pregnancy; avoid ACEi, ARB, nitroprusside 2025 ACC/AHA BP
Sympathomimetic / cocaine intoxication	Phentolamine or benzodiazepines + nicardipine	α-blockade directly reverses catecholamine excess; avoid β-blocker monotherapy (unopposed α) 2025 ACC/AHA BP
Scleroderma renal crisis	ACE inhibitor (PO/IV)	ACEi is disease-modifying; BP control is secondary to renal recovery 2025 ACC/AHA BP
Postoperative hypertension	Treat only when symptomatic; esmolol or clevidipine if needed	Shortest durations for rapid titration; avoid hydralazine IV Bakkila 2026 2025 ACC/AHA BP

IV Dosing for Hypertensive Emergency

Medication	Load	Initial Rate	Titration	Maximum
Nicardipine	—	5 mg/hr 2025 ACC/AHA BP	+2.5 mg/hr q5min	15 mg/hr
Sodium Nitroprusside	—	0.3–0.5 mcg/kg/min 2025 ACC/AHA BP	+0.5 mcg/kg/min q5min	10 mcg/kg/min
Labetalol	0.3–1 mg/kg (MAX 20 mg) 2025 ACC/AHA BP	N/A	Bolus 20–80 mg q10min until target	300 mg cumulative
Esmolol	500 mcg/kg over 1 min 2025 ACC/AHA BP	50–150 mcg/kg/min	Titrate to HR/BP	200 mcg/kg/min

Nicardipine: Good for most cases. Avoid in cirrhosis; can accumulate and cause hypotension. Reduce to 3–5 mg/hr once target reached 2025 ACC/AHA BP.

Nitroglycerin: Preferred in SCAPE or ACS. Low doses: venodilation. High doses: veno- and arterial dilation.

Nitroprusside: Can increase ICP. Cyanide toxicity / lactic acidosis. Wide BP swings. Coronary steal.

Transition to Oral Therapy

Once the patient is hemodynamically stable and target-organ damage is improving, transition to oral antihypertensives. Use the patient’s pre-admission regimen when available, with dose adjustments as needed Peixoto 2019.

Nifedipine XR: Start 30–60 mg daily. Onset 2–4 hr, duration 24 hr. Avoid immediate-release 2025 ACC/AHA BP.
Labetalol PO: Cross-titrate by downtitrating IV labetalol PRN. Start 200 mg q12h, may redose once in 4 hr; max 1000 mg q12h 2025 ACC/AHA BP.
Amlodipine: Not useful for acute transition — peak onset 6–12 hr, long half-life 2025 ACC/AHA BP.
Metoprolol: Weak antihypertensive effect; use only when β-blockade is indicated for a separate indication (IHD, HF) Peixoto 2019.
Carvedilol: Takes >24 hr to reach steady state; not useful for acute BP control Taler 2018.

Asymptomatic Elevated BP in Acute Care

Asymptomatic elevated BP in the emergency department or inpatient setting (previously called “hypertensive urgency”) is elevated BP without acute target-organ damage. The AHA acute-care scientific statement notes that the risk-benefit ratio of initiating or intensifying antihypertensives for asymptomatic elevated inpatient BP is unclear, and observational studies have suggested potential harms 2024 AHA Acute-Care BP Statement.

Key principles 2024 AHA Acute-Care BP Statement:

Do not treat asymptomatic elevated BP with IV antihypertensives 2024 AHA Acute-Care BP Statement.
Acute oral BP lowering in the absence of target-organ damage may cause harm (hypotension, cerebral or coronary hypoperfusion).
Address reversible contributors: pain, anxiety, urinary retention, medication nonadherence, volume overload.
Restart or optimize the patient’s chronic oral regimen rather than adding new acute agents.
If acute oral treatment is judged necessary in a specific case, captopril, clonidine, or labetalol PO have the fastest onset Peixoto 2019. Avoid immediate-release nifedipine Peixoto 2019.
Postoperative asymptomatic hypertension should be treated only when symptomatic Bakkila 2026.